From exon 20 insertions to subcutaneous delivery and inclusive trial design, Joshua Bauml explains why the biology demanded a ...

Amivantamab plus chemotherapy achieves 34.3-month median overall survival in EGFR exon 20 insertion lung cancer, doubling ...

Tam-Peli extends median survival to 13.3 months in relapsed small-cell lung cancer, a significant improvement over topotecan ...

Trastuzumab Botidotin Phase 3 trial shows 11.1-month PFS versus 4.4 months with T-DM1 in HER2-positive breast cancer, with ...

Phase's AI clinical data platform promises smarter trial design, but before sponsors add another vendor, the activation-cycle ...

MRI surveillance alone reduced cognitive failure risk by 40% versus MRI plus radiation in SCLC patients, per phase III ...

Ivonescimab cuts death risk 27% versus pembrolizumab in Phase III NSCLC trial, with median OS of 30.8 months versus 22.6 ...

Johnson & Johnson sells Laminar program to newly formed Jaguar LAA for left atrial appendage closure technology development ...

Tam-Peli meets primary endpoint for relapsed small-cell lung cancer in phase III trial, showing OS benefit over topotecan in ...

ENERGIZE-T's Phase 3 data shows mitapivat cut transfusion burden in 258 thalassaemia patients. Here's what the trial design ...

CMO location drives site selection for Parkinsonian imaging trial, requiring geographic proximity to manufacturing over ...

Lyell completes LYL273 manufacturing transfer to its Bothell facility, though the Phase 1/2 colorectal cancer trial now faces ...